KLOW — research peptide blend (GHK-Cu + BPC-157 + TB-500 + KPV)

What KLOW is

KLOW is a research peptide blend (a composition) of four distinct substances: the copper complex GHK-Cu, the pentadecapeptide BPC-157, a thymosin β4 fragment known by the code name TB-500, and the tripeptide KPV. Each component has its own chemical structure, separate origin, and independent body of primary literature; KLOW is neither an approved medicinal product nor a clinically validated fixed combination; it is a reagent for laboratory research (RUO, research use only). The sections below describe the chemistry, structure, and published mechanism of each component, along with the rationale for combining them, strictly at the level of the reported experimental record and with no instructions for human use.

GHK-Cu (glycyl-L-histidyl-L-lysine · copper)

GHK is a natural tripeptide, Gly-His-Lys, first isolated by Pickart from human plasma as a factor that modulates cell behaviour. Its key chemical property is a high affinity for copper(II) ions: the peptide forms a stable coordination complex, GHK-Cu, in which Cu²⁺ is chelated by the imidazole nitrogen of histidine, the α-amino group of glycine, and the deprotonated amide nitrogen of the peptide bond, while the lysine side chain remains outside the coordination sphere. It is through this complex that GHK was historically regarded as a physiological carrier facilitating copper uptake into cells ^[1]. The concentration of free GHK in plasma declines with age, a trend correlated with a decline in the regenerative capacity of tissues.

In the research literature GHK and GHK-Cu are associated with extracellular-matrix remodelling: stimulation of collagen, elastin, and glycosaminoglycan synthesis, modulation of metalloproteinases and their tissue inhibitors, and antioxidant effects ^[2]. Copper is a cofactor for several enzymes (notably lysyl oxidase, which catalyses collagen and elastin cross-linking, and superoxide dismutase), so copper delivery by the GHK-Cu complex is conceptually linked both to matrix maturation and to antioxidant defence. GHK-Cu has also been described in experimental work in the context of angiogenesis, fibroblast stimulation, and recruitment of cells to a site of injury. Transcriptomic data indicate that GHK can shift the expression profile of many genes toward a pattern characteristic of a "healthy" tissue state, acting on pathways related to repair, inflammation, and control of oxidative stress ^[3]. These observations pertain chiefly to cell cultures and experimental models and are not claims of clinical efficacy.

BPC-157 (pentadecapeptide · gastric origin)

BPC-157 (Body Protection Compound 157) is a synthetic pentadecapeptide of 15 amino-acid residues, sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (GEPPPGKPADDAGLV). It is derived as a partial sequence of a larger protective protein identified in gastric juice; a defining feature is its high stability in the acidic gastric environment and resistance to hydrolysis, which is why experimental reports frequently describe the peptide as "stable", not requiring a carrier protein ^[4].

The BPC-157 research record comes chiefly from cell and animal models. In vitro the peptide promoted the migration and survival of tendon cells and stimulated their outgrowth from explants, which is interpreted as a mechanistic basis for the observed acceleration of connective-tissue healing ^[5]. A substantial fraction of the work centres on angiogenesis and interaction with the nitric-oxide (NO) system: effects on the VEGFR2-eNOS signalling pathway are described, as is engagement of the so-called brain-gut axis, which is linked to cytoprotective effects across several organ systems ^[6]. Several experimental models have also noted BPC-157's interaction with the growth-hormone receptor in fibroblasts and its ability to counter mucosal injury induced by non-steroidal anti-inflammatory drugs.

TB-500 / thymosin β4 (actin binding)

Thymosin β4 (Tβ4) is an acidic 43-residue polypeptide (≈4.9 kDa), the principal intracellular sequestering protein of monomeric (G-)actin in mammalian cells: it binds actin in a 1:1 stoichiometry and thereby regulates the equilibrium between globular and filamentous actin, and hence cytoskeletal dynamics ^[7]. Actin binding is governed by the central LKKTET motif (residues ~17–23); TB-500 is a common name for a synthetic fragment built around this actin-binding domain of Tβ4.

The name "thymosin" reflects the peptide's original isolation from thymus tissue, although it was later found in virtually all cell types, where it constitutes a substantial intracellular pool of G-actin. Beyond actin regulation, Tβ4 is described in the research literature as a "multi-functional" repair peptide: it showed pro-angiogenic activity, promoted cell migration, and modulated the inflammatory response in tissue-repair models ^[8]. In dermatological experimental models in particular, Tβ4 accelerated wound healing by enhancing cell migration and granulation-tissue formation ^[9]; repair effects have also been studied in corneal and myocardial models. It should be stressed that these data belong to the preclinical domain and describe the molecular biology of the peptide, not therapeutic recommendations.

KPV (C-terminal tripeptide of α-MSH)

KPV is the tripeptide Lys-Pro-Val, corresponding to the C-terminal region (residues 11–13) of α-melanocyte-stimulating hormone (α-MSH). This short "message" sequence retains the anti-inflammatory properties of the parent hormone but lacks its melanotropic (pigmentary) activity, which makes KPV a convenient model object for studying the anti-inflammatory effects of melanocortins.

Mechanistically, KPV is associated with suppression of pro-inflammatory signalling, in particular activation of the transcription factor NF-κB and the production of pro-inflammatory cytokines. The tripeptide has been shown to enter epithelial and immune cells via the peptide transporter PepT1, and this uptake is associated with reduced intestinal inflammation ^[10]. In murine models of inflammatory bowel disease, KPV displayed anti-inflammatory potential, attenuating the severity of experimental colitis ^[11]. Because KPV exerts its effect after entering the cell, its action is largely regarded as independent of the classical melanocortin receptors at the cell surface; analogues with improved resistance to proteolysis, including ones bearing D-amino acids, have also been studied. The broader biochemistry of α-MSH and its derived tripeptides is systematised in review literature, which highlights their role as anti-inflammatory and immunomodulatory agents ^[12].

Component types and dosage

Important: the values below are typical ranges cited in research literature for each component separately, for reference only. KLOW is a physical mixture of four distinct peptides in one vial, not a single clinically studied molecule; there is no pooled clinical data for this specific combination. This is not a usage recommendation; the product is intended for laboratory research only, not for use in humans or animals.

The BPC-157 and TB-500 figures match the same reference protocols as the standalone BPC-157 and TB-500 pages. GHK-Cu and especially KPV data are less standardized: human clinical research on injectable KPV is substantially thinner than for the other three components.

Rationale of the blend

The logic of combining four substances in KLOW rests on the complementarity of their documented mechanisms rather than on any clinically demonstrated synergy. In research, GHK-Cu is associated with copper delivery and matrix remodelling; BPC-157 with angiogenesis and cytoprotection; the Tβ4/TB-500 fragment with actin dynamics and cell migration; and KPV with control of inflammation. These themes (angiogenesis, cell migration, synthesis and remodelling of the extracellular matrix, and modulation of inflammation) recur repeatedly in the tissue-repair literature, so combining the components into a single reagent is rational precisely for comparative research purposes. Importantly, no controlled clinical trials of the blend itself exist, and the preponderance of primary data was obtained in vitro and in animals; any conclusions about how the components interact within KLOW therefore remain hypotheses to be tested experimentally.

Physicochemistry and formulation notes

KLOW is a mixture of a metal-peptide complex with three synthetic peptides, each with its own charge profile. In solution GHK-Cu has a characteristic blue-violet colour arising from d-d transitions of the coordinated copper(II); BPC-157, the Tβ4 fragment, and KPV are white to off-white lyophilised powders. All components are water-soluble but differ in isoelectric point: BPC-157 and Tβ4 are acidic (rich in Asp/Glu residues), whereas GHK and KPV carry a basic lysine residue. Because of the redox-active copper centre, the formulation should be protected from strong reducing agents and competing chelators capable of disrupting the GHK-Cu complex; co-storing peptides of different pI in solution also calls for attention to buffer compatibility.

Analytical characterisation

Confirming the identity and purity of the individual components uses the standard peptide-analytical toolkit: reversed-phase HPLC (RP-HPLC) for purity, mass spectrometry (ESI-MS or MALDI-TOF) to confirm molecular masses and sequences, amino-acid analysis, and determination of net peptide content and residual trifluoroacetate counter-ion. For the copper complex, UV-Vis spectroscopy (the copper absorption band in the ~600–650 nm region) and elemental copper analysis (AAS or ICP) are additionally appropriate for verifying the Cu:peptide stoichiometry. Residual moisture (Karl Fischer) and endotoxin level are also routinely controlled. Because KLOW is multi-component, correct characterisation requires profiling each substance separately, not merely a bulk analysis of the mixture.

Handling, reconstitution, and storage

As a research reagent, KLOW is typically supplied lyophilised. General laboratory practice for such peptides calls for dry storage at −20 °C, protection from light and moisture, and avoidance of repeated freeze-thaw cycles of the reconstituted solution. Reconstitution is performed with sterile or bacteriostatic water for laboratory purposes; the copper component is additionally sensitive to contact with reducing agents and chelators, so freshly reconstituted aliquots are best used without prolonged storage. KLOW is intended for research use only (RUO) and is not a product for diagnosis, prevention, or treatment; it is not for use in humans or animals outside a properly controlled scientific experiment.